Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : The thread of life -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (824)	10/5/2005 10:52:19 PM
From: Mike McFarland	Read Replies (1) \| Respond to of 1336

I don't think DPI lists competitors in the quarterly reports (hmmm, might be time to read one again) but as of 2003 they had this: I don't remember coming across Cerep, Mimotopes or Biofocus. º Assay development and screening, including Cerep, Evotec OAI AG, Pharmacopeia and Tripos; º Combinatorial chemistry instruments, including Argonaut and Mimotopes; º Compound libraries and lead optimization, including Albany Molecular Research, Pharmacopeia, Array Biopharma, Evotec OAI AG, Biofocus and ArQule; º Informatics, including Accelrys and Tripos; and º Gene profiling, including Affymetrix and Gene Logic. That is right--I don't see any specific competitors mentioned in the current report. Ha, this risk is amusing--Our stock price will likely be volatile. Only 3000 shares traded today--lately the stock is often very thinly traded, but certainly not volatile today. Sort of an interesting combination for a change. For awhile it looked sorta daytradable from 3.2 to 3.4. But not today. edit, Cerep and Mimotopes are indeed on a list: Message 21749240 edit, Biofocus was Nigel's number one pick for the contest, but I see by the chart the buyout only brought the shareprice back to about even for the year.